IDO1 and neoplasm: Although this may partially be compensated for by the considerably higher AhR-activating potency of indole-3-pyruvic acid compared to IDO1-generated metabolites (37), it remains unclear whether IL4I1 is capable of achieving significant AhR activation in most tumor types.